Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-14 4:19 pm Purchase |
2024-12-31 | 13G | Prelude Therapeutics Incorporated PRLD |
Vaddi Krishna | 5,489,130 9.500% |
581,044 (+11.84%) |
Filing History |
| 2025-02-13 08:58 am Sale |
2024-12-31 | 13G | Prelude Therapeutics Incorporated PRLD |
Flynn James E | 0 0.000% |
-4,133,000 (Position Closed) |
Filing History |
| 2024-02-13 1:34 pm Sale |
2023-12-31 | 13G | Prelude Therapeutics Incorporated PRLD |
UBS GLOBAL ASSET MANAGEMENT AMERICAS INC | 0 0.000% |
-2,507,992 (Position Closed) |
Filing History |
| 2024-02-12 5:30 pm Purchase |
2023-12-31 | 13G | Prelude Therapeutics Incorporated PRLD |
Flynn James E | 4,133,000 9.850% |
910,310 (+28.25%) |
Filing History |
| 2024-02-12 4:26 pm Purchase |
2023-12-31 | 13G | Prelude Therapeutics Incorporated PRLD |
Vaddi Krishna | 4,908,086 11.100% |
608,763 (+14.16%) |
Filing History |
| 2024-01-10 08:53 am Sale |
2024-01-09 | 13G | Prelude Therapeutics Incorporated PRLD |
FMR CORP | 264,686 0.630% |
-4,613,865 (-94.57%) |
Filing History |
| 2023-12-13 4:55 pm Purchase |
2023-12-11 | 13D | Prelude Therapeutics Incorporated PRLD |
Baker Bros. Advisors LP | 10,222,968 24.300% |
3,888 (+0.04%) |
Filing History |
| 2023-11-13 08:30 am Purchase |
2023-11-02 | 13G | Prelude Therapeutics Incorporated PRLD |
Flynn James E | 3,222,690 7.680% |
3,222,690 (New Position) |
Filing History |
| 2023-05-24 4:47 pm Purchase |
2023-05-22 | 13D | Prelude Therapeutics Incorporated PRLD |
ORBIMED ADVISORS LLC | 15,716,642 28.600% |
869,565 (+5.86%) |
Filing History |
| 2023-05-24 4:31 pm Purchase |
2023-05-18 | 13D | Prelude Therapeutics Incorporated PRLD |
Baker Bros. Advisors LP | 10,219,080 19.500% |
92,663 (+0.92%) |
Filing History |
| 2023-02-13 10:52 am Purchase |
2022-12-30 | 13G | Prelude Therapeutics Incorporated PRLD |
UBS GLOBAL ASSET MANAGEMENT AMERICAS INC | 2,507,992 5.240% |
2,507,992 (New Position) |
Filing History |
| 2023-02-10 09:08 am Purchase |
2023-02-09 | 13G | Prelude Therapeutics Incorporated PRLD |
FMR CORP | 4,878,551 10.193% |
288,960 (+6.30%) |
Filing History |
| 2023-02-10 08:00 am Purchase |
2022-12-31 | 13G | Prelude Therapeutics Incorporated PRLD |
Vaddi Krishna | 4,299,323 11.300% |
680,770 (+18.81%) |
Filing History |
| 2023-02-09 12:31 pm Sale |
2023-02-09 | 13G | Prelude Therapeutics Incorporated PRLD |
FMR CORP | 4,589,591 9.589% |
-1,349,341 (-22.72%) |
Filing History |
| 2022-02-09 10:24 am Sale |
2022-02-08 | 13G | Prelude Therapeutics Incorporated PRLD |
FMR CORP | 5,938,932 12.578% |
-413,049 (-6.50%) |
Filing History |
| 2022-02-04 4:05 pm Purchase |
2021-12-31 | 13G | Prelude Therapeutics Incorporated PRLD |
Vaddi Krishna | 3,618,553 9.700% |
680,781 (+23.17%) |
Filing History |
| 2021-02-11 4:06 pm Purchase |
2020-12-31 | 13G | Prelude Therapeutics Incorporated PRLD |
Vaddi Krishna | 2,937,772 12.620% |
2,937,772 (New Position) |
Filing History |
| 2021-02-10 09:23 am Purchase |
2021-02-09 | 13G | Prelude Therapeutics Incorporated PRLD |
FMR CORP | 6,351,981 13.747% |
2,142,018 (+50.88%) |
Filing History |
| 2021-02-08 10:31 am Purchase |
2021-02-05 | 13G | Prelude Therapeutics Incorporated PRLD |
FMR CORP | 4,209,963 9.633% |
4,209,963 (New Position) |
Filing History |
| 2021-01-29 4:48 pm Purchase |
2021-01-22 | 13D | Prelude Therapeutics Incorporated PRLD |
Baker Bros. Advisors LP | 10,126,417 28.800% |
5,189 (+0.05%) |
Filing History |